APP and Alzheimer disease: Rolipram, a phosphodiesterase E4 (PDE4) inhibitor has been tested only preclinically, with encouraging results, as APP/PS1 mouse model of AD develops LTP deficits, but rolipram-treated APP/PS1 mice show comparable LTP induction to wild type mice [106,107], (Table 1).